Pralsetinib in Patients with Advanced/Metastatic Rearranged During Transfection (RET)-Altered Thyroid Cancer: Updated Efficacy and Safety Data from the ARROW Study.

Authors

• Vivek Subbiah
• Mimi I Hu
• Aaron S Mansfield
• Matthew H Taylor
• Martin Schuler
• Viola W Zhu
• Julien Hadoux
• Giuseppe Curigliano
• Lori Wirth
• Justin F Gainor
• Guzman Alonso
• Douglas Adkins
• Yann Godbert
• Myung-Ju Ahn
• Philippe A Cassier
• Byoung Chul Cho
• Chia-Chi Lin
• Alena Zalutskaya
• Teresa Barata
• Peter Trask
• Astrid Scalori
• Walter Bordogna
• Sebastian Heinzmann
• Marcia S Brose

Publication/Presentation Date

1-1-2024

Volume

34

Issue

1

First Page

26

Last Page

40

ISSN

1557-9077

Published In/Presented At

Subbiah, V., Hu, M. I., Mansfield, A. S., Taylor, M. H., Schuler, M., Zhu, V. W., Hadoux, J., Curigliano, G., Wirth, L., Gainor, J. F., Alonso, G., Adkins, D., Godbert, Y., Ahn, M. J., Cassier, P. A., Cho, B. C., Lin, C. C., Zalutskaya, A., Barata, T., Trask, P., … Brose, M. S. (2024). Pralsetinib in Patients with Advanced/Metastatic Rearranged During Transfection (RET)-Altered Thyroid Cancer: Updated Efficacy and Safety Data from the ARROW Study. Thyroid : official journal of the American Thyroid Association, 34(1), 26–40. https://doi.org/10.1089/thy.2023.0363

Disciplines

Medicine and Health Sciences

PubMedID

38009200

Department(s)

Hematology-Medical Oncology Division

Document Type

Article